Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Interest & Investment Income (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Interest & Investment Income for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 17.55% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 18.76% year-over-year, with the annual reading at $9.9 million for FY2025, 18.76% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $2.4 million at Fulcrum Therapeutics, up from $2.3 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $3.5 million in Q2 2023, with the low at $34000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $1.9 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income plummeted 87.21% in 2021, then skyrocketed 4415.71% in 2023.
  • Over 5 years, Interest & Investment Income stood at $75000.0 in 2021, then skyrocketed by 2350.67% to $1.8 million in 2022, then soared by 76.06% to $3.2 million in 2023, then decreased by 11.59% to $2.9 million in 2024, then fell by 17.55% to $2.4 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $2.4 million, $2.3 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.